Literature DB >> 7979917

Pseudomyxoma peritonei. Histologic predictors of patient survival.

M J Costa1.   

Abstract

Pseudomyxoma peritonei is uncommon and the histopathologic predictors of patient survival with this disease have not been investigated extensively. The clinicopathologic features of 35 patients with pseudomyxomatous peritoneal implants (implants that produced extracellular mucin) were compared with a control group of 90 consecutive patients with peritoneal implants without extracellular mucin. The histologic patterns of these nonpseudomyxomatous implants were as follows: glandular, 43%; serous, 21%; signet ring, 20%; solid, 13%; and clear cell, 2%. The pseudomyxomatous implants were more likely to have originated from a mucinous epithelial tumor of the appendix (31% vs 1%). Other primary sites produced pseudomyxomatous and nonpseudomyxomatous implants with similar frequency: colon (26% vs 30%), ovary (23% vs 16%), stomach (11% vs 10%), small intestine (3% vs 1%), urinary bladder (3% vs 1%), endometrium (0% vs 10%), prostate gland (0% vs 6%), and unknown (3% vs 15%). Three-year follow-up was available for 29 of 35 and 71 of 90 patients with and without extracellular mucin in their implants, respectively. The patients with pseudomyxomatous implants survived longer (24% vs 4% survival at 3 years). Three-year follow-up was available for 90 of 110 and 10 of 15 patients with and without invasion in the primary tumor or its peritoneal implants, respectively. The patients without invasive tumors survived longer (80% vs 4% survival at 3 years). Invasion in the primary tumor or its implants, present in 21 of 35 pseudomyxomatous implants, eliminated any improved survival associated with the presence of extracellular mucin. Prolonged survival in pseudomyxoma peritonei was associated with the histologic findings of noninvasive implants arising from mucinous epithelial tumors of low malignant potential histology. In our study, such tumors originated in the appendix (eight cases [23%]) and ovary (five cases [14%]) among the total number of 35 patients.

Entities:  

Mesh:

Year:  1994        PMID: 7979917

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  5 in total

1.  Pseudomyxoma peritonei arising from intraductal papillary neoplasm after surgical pancreatectomy: report of 2 cases and review of the literature.

Authors:  Hiroshi Imaoka; Kenji Yamao; Susumu Hijioka; Kazuo Hara; Nobumasa Mizuno; Tsutomu Tanaka; Shinya Kondo; Masahiro Tajika; Yasuhiro Shimizu; Yasumasa Niwa
Journal:  Clin J Gastroenterol       Date:  2011-12-21

2.  Pseudomyxoma peritonei: disseminated peritoneal adenomucinosis variant.

Authors:  Anshuman Pandey; Ashish Kumar Mishra
Journal:  BMJ Case Rep       Date:  2011-05-03

3.  Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells.

Authors:  Jerome T O'Connell; James S Tomlinson; Alice A Roberts; Kathryn F McGonigle; Sanford H Barsky
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

4.  Establishment and Characterization of NCC-PMP1-C1: A Novel Patient-Derived Cell Line of Metastatic Pseudomyxoma Peritonei.

Authors:  Rei Noguchi; Yuki Yoshimatsu; Yooksil Sin; Takuya Ono; Ryuto Tsuchiya; Hiroshi Yoshida; Tohru Kiyono; Yutaka Yonemura; Tadashi Kondo
Journal:  J Pers Med       Date:  2022-02-10

5.  Development and validation of prognostic nomograms for pseudomyxoma peritonei patients after surgery: A population-based study.

Authors:  Peng Chen; Lan Su; Wenming Yang; Jianhao Zhang; Yong Wang; Cun Wang; Yongyang Yu; Lie Yang; Zongguang Zhou
Journal:  Medicine (Baltimore)       Date:  2020-07-31       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.